Epigral Delivers Strong Q2 FY27 Revenue Growth Amid Specialty Expansion
Epigral Ltd · Investor Presentation · 02 Nov 2026, 7:32 pm
Epigral Delivers Strong Q2 FY27 Revenue Growth Amid Specialty Expansion Epigral reported Q2 FY27 revenue growth of 28% YoY to ₹752 Cr, supported by a 6% YoY sales volume increase and improved realizations. Derivatives & Specialty chemicals contributed 57% of total revenue. EBITDA rose 3% YoY to ₹136 Cr, with margins contracting to 18% due to elevated raw material costs, while PAT grew 26% YoY to ₹64 Cr. For H1 FY27, revenue reached ₹1,461 Cr and PAT stood at ₹164 Cr. Expansions in CPVC and ECH are scheduled for commissioning in Q3 FY27.
Original exchange filing (PDF)
More announcements from Epigral Ltd
- One-on-One Meeting through Video Conferencing (V.C.) with Kotak Mahindra Asset Management (Singapore) Pte Ltd on Thursday, 19th November, 2026. · 18 Nov 2026
- One-on-One Meeting through Video Conferencing (V.C.) with Kitara Capital on Friday, 20th November, 2026. · 18 Nov 2026
- Epigral Limited submits Transcript of conference call held on Monday, 2nd November, 2026 discussing Q2 FY2027 Results. · 08 Nov 2026
- Audio Recording of Conference Call discussing Q2 FY27 Results held on Monday, 2nd November, 2026 at 5.00 P.M. · 03 Nov 2026
- PRESS RELEASE - RESULTS- Q2 FY27. · 02 Nov 2026
- UNAUDITED FINANCIAL RESULTS - 30.09.2026 · 02 Nov 2026
- Epigral Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 02 Nov 2026
- Outcome of Board Meeting held on Monday, 2nd November, 2026 and submission of Un-Audited Financial Results (Standalone & Consolidated) for the Second Quarter and Half Year ended 30th, September, 2026 · 02 Nov 2026
